You searched for: gonadotropiini (Estniska - Engelska)

gonadotropiini
gonadotropin

farmakoterapeutiline grupp: gonadotropiini vabastav hormoon .
pharmaceutical group: gonadotrophin-releasing hormone.

pärast ravi gonadotropiini preparaatidega suureneb mitmikraseduse risk.
after treatment with gonadotrophin preparations, there is an increased risk of having multiple pregnancies.

gonadotropiini vabastav hormoon (gnrh) atcvet kood:
gonadotrophin-releasing hormone (gnrh) atcvet code:

neerupealise koore puudulikkus, langenud gonadotropiini tase veres
adrenal insufficiency, blood gonadotropin decreased

farmakoterapeutiline rühm: gonadotropiini vabastava faktori analoogvalgu konjugaat.
pharmacotherapeutic group: gonadotropin releasing factor analogue, conjugated.

gonadotropiini vabastav hormoon sünteesitakse selgroogsete loomade hüpotaalamuse neuronites.
gnrh is synthesised by neurones in the hypothalamus in all vertebrate species.

asaglünafareliin on gonadotropiini vabastava hormooni (gnrh) sünteetiline analoog.
azagly-nafarelin is a synthetic analogue of gonadotrophin-releasing hormone (gnrh).

nendel naistel tuleb võrrelda gonadotropiini manustamisest saadavat kasu ja riske.
in these women the benefits of gonadotropin administration need to be weighed against the risks.

sugunäärmete talitluse ärahoidmine emastel koertel gonadotropiini sünteesi pikaajalise blokeerimise teel.
prevention of gonadal function in bitches via long term blockade of gonadotrophin synthesis.

- Ülitundlikkus gonadotropiini vabastava hormooni (gnrh) või mõne teise gnrh analoogi
− hypersensitivity to the active substance or to any of the excipients. − hypersensitivity to gonadotrophin-releasing hormone (gnrh) or any other gnrh analogue − moderate or severe impairment of renal or hepatic function − pregnancy or lactation.

cetrotide kuulub „gonadotropiini vabastamist takistavate hormoonide“ nimelisse ravimite rühma.
cetrotide belongs to a group of medicines called ‘anti-gonadotropin-releasing hormones’.

- kui te olete ülitundlik gonadotropiini vabastajahormooni (gnrh) või gnrh analoogi suhtes.
do not use orgalutran, − if you are allergic (hypersensitive) to ganirelix or any of the other ingredients of orgalutran; − if you are hypersensitive to gonadotrophin releasing hormone (gnrh) or a gnrh analogue; − if you have a moderate or severe kidney or liver disease; − if you are pregnant or breast-feeding.

kõigi gonadotropiini sisaldavate ravirežiimidega, sealhulgas elonvaga, on teatatud mitmikrasedustest ja -sünnitustest.
multiple pregnancies and births have been reported for all gonadotropin treatments, including elonva.

sümptomite ja vastavate ravimeetmete rakendamise suhtes lugege teile välja kirjutatud gonadotropiini sisaldava ravimi pakendi infolehte.
for symptoms and suitable measures please refer to the patient information leaflet of the gonadotropin-containing medicine prescribed for you.

degareliks jäljendab kehaomase hormooni (gonadotropiini vabastajahormoon, gnrh) ja blokeerib otseselt selle toimeid.
degarelix mimics a natural hormone (gonadotrophin-relasing hormone, gnrh) and directly blocks its effects.

see sündroom on seotud gonadotropiinidega stimuleerimise protseduuriga; palun lugege teile määratud gonadotropiini sisaldava ravimi pakendi infolehte.
15 during or following hormonal stimulation of the ovaries ovarian hyperstimulation syndrome may develop; this syndrome is related to the stimulation procedure with gonadotrophins; please refer to the package leaflet of the gonadotrophin-containing medicine prescribed for you.

firmagon on gonadotropiini vabastajahormooni (gnrh) antagonist, mis on näidustatud kaugelearenenud hormoonsõltuva eesnäärmevähiga patsientide raviks.
firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer.

improvac on kultidele ette nähtud immunoloogiatoode, mis sisaldab toimeainena gonadotropiini vabastava faktori (gnrf) analoogvalgu konjugaati.
improvac is an immunological product intended for male pigs that contains a gonadotropin releasing factor (gnrf) analogue-protein conjugate as the active substance.

blokeerides gonadotropiini vabastajahormooni (gnrh) toime, peatab orgalutran luteiniseeriva hormooni tekkimise ja hoiab sel viisil ära enneaegse ovulatsiooni.
by blocking the effect of gnrh, orgalutran stops the production of lh, and therefore prevents premature ovulation.